Podcasts about ghrh

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Vídeo patrocinado por Belevels. Si quieres probar sus productos, con el código PROFECLAUDIO tienes descuento en su web. https://belevels.com/ ¿Sabes que tu cuerpo tiene un sistema interno que decide cuándo reparar, cuándo regenerar músculo y cuándo movilizar grasa? No es un suplemento. No es magia. Es el eje Hipotálamo–Hipófisis–Somatotropina (GH) y su relación con IGF-1 (Somatomedina C). En este vídeo te explico con rigor y ciencia: • Cómo funciona realmente el eje HHGH • Qué papel tienen GHRH y Somatostatina • Por qué la GH se libera en pulsos • Por qué el sueño profundo (fase N3) es clave • Qué relación tiene la GH con la regeneración muscular • Qué bloquea este sistema (estrés, alcohol, resistencia a la insulina…) • Y por qué muchas veces el problema no es “déficit hormonal”, sino déficit de sueño Si no duermes bien, no activas correctamente tu mayor pulso fisiológico de somatotropina. Y sin pulso nocturno… no hay mantenimiento óptimo. La fisiología no funciona por hacks. Funciona por ritmos. Si te interesa la fisiología aplicada al rendimiento, la recuperación y la salud metabólica, suscríbete

In this video, I review sermorelin, a growth hormone–elevating peptide, and explain where it fits physiologically within the growth hormone axis. I begin by defining what peptides are and what is meant by a growth hormone–elevating peptide, then clarify what sermorelin is — and what it is not. HOW SERMORELIN WORKS, Sermorelin is a synthetic analog of growth hormone–releasing hormone (GHRH). It acts at the level of the pituitary gland to stimulate endogenous, pulsatile growth hormone secretion, rather than providing exogenous growth hormone. I discuss the downstream effects of growth hormone signaling, including its role in: ❇️ sleep regulation ❇️ bone metabolism ❇️ muscle and body composition ❇️ skin integrity ❇️ cognitive function I also address a common question: Why don't we simply administer growth hormone? This section reviews the physiologic risks of bypassing hypothalamic–pituitary regulation, including suppression of natural hormone signaling and elevations in IGF-1. Finally, I conclude with an overview of clinical considerations surrounding administration, including dosing, timing, and cost. My goal is to help you understand where sermorelin fits within normal hormone physiology, so you can make informed, thoughtful decisions about your care. If you would like a physician-guided evaluation, you can visit us at Complete Midlife Wellness Center https://completemidlifewellnesscenter.com

Today, we're talking about tesamorelin, a peptide that works through the growth hormone pathway and is especially effective when it comes to targeting stubborn belly fat. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ So, what exactly is tesamorelin? In simple terms, it's a synthetic growth hormone-releasing hormone (GHRH) analog—basically, it signals your pituitary gland to release more growth hormone (GH). Why does that matter? Because GH plays a big role in fat metabolism, especially when it comes to visceral fat, the deep fat that surrounds your organs in your abdominal region. Here's how it works: when GH levels rise, your body starts breaking down fat for energy—a process called lipolysis. Visceral fat, in particular, is very responsive to GH. Reducing this type of fat isn't just about looking better; it also improves metabolic health, boosts insulin sensitivity, and lowers inflammation, all of which support long-term health and reduce your risk of heart disease. Why not just give GH directly? Your body only produces a certain amount of GH naturally, and this declines with age. Giving exogenous GH can boost levels quickly, but it comes with higher risks like swelling, joint pain, and sometimes insulin resistance if overused.  Tesamorelin, on the other hand, stimulates your own pituitary gland to release GH naturally, which tends to be safer and more physiologic over time. That said, GH injections might be preferred in certain clinical scenarios, but for most people, tesamorelin offers a more controlled approach. What about side effects? Some common ones include joint pain, swelling, and muscle aches. These happen because GH causes fluid retention and increased tissue growth, which can put pressure on joints and muscles.  Also, tesamorelin can slightly increase blood sugar, so people with diabetes or prediabetes should be monitored carefully. But why does this happen? Since tesamorelin works by boosting your growth hormone, it can have an impact on how your body handles glucose. Growth hormone naturally makes your body a little less sensitive to insulin, which means your cells don't take up sugar as efficiently. So, some people might notice a slight rise in fasting blood sugar when they start using tesamorelin. But here's the interesting part: growth hormone also increases IGF-1, which has some insulin-like effects. In most healthy people, this helps balance things out, so blood sugar doesn't spike dramatically. But if someone already has prediabetes or type 2 diabetes, it's something to keep an eye on. The takeaway? Tesamorelin can slightly raise blood sugar, but it's usually manageable. Regular monitoring is smart, especially for anyone with a history of blood sugar issues. And compared to direct growth hormone injections, tesamorelin tends to have less of an effect on blood sugar because it stimulates your body to release GH naturally, instead of flooding your system with it. Typical dosing of tesamorelin For men, peptide therapy is often 1 mg at night to support natural GH peaks during sleep, and 1 mg in the morning before fasted cardio or exercise. Women usually do 1 mg daily. Tesamorelin can be expensive, so many people cycle it 5 days on, 2 days off to reduce cost, or just do 1 mg at night, which still supports GH production and can even improve sleep. Typically, tesamorelin is cycled for 8 weeks on, then 8 weeks off, and most people start noticing results after 4 to 6 weeks. This cycling helps manage cost, reduce potential side effects, and allows the body to maintain responsiveness to the therapy. My Final thoughts Tesamorelin is a powerful tool for targeting visceral fat and improving body composition safely through your natural GH pathways. It's not a cheap therapy, but if used strategically—especially timed with sleep or exercise—it can give great results while minimizing side effects. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.

Join our free community, The Women's Peptide Collective, click the Skool link to become a member and to connect, learn, and collaborate. https://www.skool.com/womens-peptide-collective-9663Go to https://thepeptique.com/ to get all your research peptides .As a loyal listener use the discount code POD15 to get 15% off the entire line of products.Have questions? Feel free to reach out to me: tarawest@westwellnessatx.comWant the free peptide guide? Email me tarawest@westwellnessatx.com and comment Guide and I'll shoot it right over!Follow me on instagram AND TikTOk @westwellnessatxTakeaways: In this podcast episode, we delve into the complexities of growth hormone secretagogue peptides, exploring their distinctive functionalities, benefits, and potential side effects. We discuss the significance of understanding terms such as half-life and GHRH, which are pivotal in comprehending how different peptides operate within the body. The episode emphasizes the importance of cycling peptides to maintain receptor sensitivity and avoid diminishing returns from continuous use, ensuring optimal efficacy. Listeners are advised to consider individual goals when selecting peptides, as different combinations can yield varying results based on desired outcomes and health status. Links referenced in this episode:skooLpeptique

Today, we're diving into an exciting peptide therapy called tesamorelin. You might have heard of it if you're interested in anti-aging treatments.  In this episode, we'll break down exactly what tesamorelin is, how it works in the body, and the potential benefits it can offer. Plus, we'll talk about the possible side effects and risks associated with the therapy, and how it compares to another popular peptide we discussed last week, sermorelin.  What is Tesamorelin? Tesamorelin is a synthetic peptide that acts as a growth hormone-releasing hormone (GHRH) analog. In simple terms, it stimulates the body's natural production of growth hormone (GH) by targeting the pituitary gland, which is responsible for releasing growth hormone.  Unlike direct growth hormone replacement therapy, where you inject synthetic growth hormone into your body, tesamorelin works by prompting your body to produce its own growth hormone naturally. This is often considered a more natural approach to restoring optimal hormone levels. Originally, tesamorelin was approved by the FDA to treat lipodystrophy (abnormal fat distribution) in HIV patients who were experiencing excess abdominal fat. However, its use has since expanded in the realm of anti-aging and fat loss due to its ability to promote fat metabolism, muscle development, and overall vitality. How Does Tesamorelin Work? In essence, tesamorelin taps into your body's natural ability to produce growth hormone, rather than injecting it directly. This is why it's often considered a safer, less invasive alternative to traditional growth hormone therapy. It's typically given once daily via subcutaneous injections (just under the skin). Depending on the health condition being treated, some individuals may need to dose less frequently. What's the Difference Between Tesamorelin and Sermorelin? While both tesamorelin and sermorelin are peptides that stimulate the release of growth hormone, they differ in their structure and the specific ways they interact with the body. Tesamorelin is a modified version of GHRH that specifically targets the release of growth hormone from the pituitary gland. It's particularly effective in reducing abdominal fat (especially visceral fat) and improving body composition, which makes it popular for individuals seeking fat loss and anti-aging benefits. Sermorelin, on the other hand, is a shorter form of GHRH and has a more general effect on growth hormone secretion. While it also stimulates the pituitary to release growth hormone, it is often used in younger individuals or those seeking overall growth hormone balance and anti-aging benefits rather than specifically targeting fat loss. Potential Benefits of Tesamorelin Therapy Fat Loss and Body Composition: One of the most well-known benefits of tesamorelin is its ability to reduce abdominal fat and improve overall body composition. It is especially effective at targeting visceral fat, the fat stored around internal organs. This can be beneficial for those looking to lose stubborn belly fat, which is linked to several health issues like heart disease, diabetes, high blood pressure, and fatty liver disease. Improved Muscle Mass: Since growth hormone plays a key role in muscle development, tesamorelin can help increase lean muscle mass and improve muscle tone. It's especially helpful for older adults or people recovering from injuries who want to retain or regain muscle strength. Increased Energy Levels: Higher levels of growth hormone can result in improved energy, vitality, and endurance. Many patients report feeling more energized throughout the day, which can improve quality of life and overall activity levels. Better Skin and Hair Health: Tesamorelin's effects on collagen production can contribute to improved skin tone, elasticity, and texture. It may also benefit hair health, making it a popular option for individuals seeking anti-aging benefits beyond just fat loss and muscle gain. Improved Metabolism: Tesamorelin may enhance the body's metabolism, aiding in better fat burning and more efficient use of nutrients, which can be beneficial for weight management. Cognitive Function: Some studies suggest that tesamorelin may have cognitive benefits, including improved memory and mental clarity, likely due to the overall boost in growth hormone levels. Potential Side Effects and Risks As with any therapy, tesamorelin comes with potential side effects and risks. While side effects are generally mild and well-tolerated, they can include: Injection site reactions: Pain, redness, or swelling at the injection site. Headaches: Some people report mild to moderate headaches, especially when first starting the therapy. Joint pain or muscle aches: Increased growth hormone levels can sometimes lead to discomfort in muscles or joints. Fluid retention: Some individuals may notice mild swelling or bloating, particularly in the hands or feet. Long-term use of growth hormone-stimulating therapies like tesamorelin may increase the risk of carpal tunnel syndrome, joint issues, or diabetes in predisposed individuals.  Although rare, there is a concern that stimulating growth hormone production could accelerate the growth of existing cancers, so it's important to have a thorough health evaluation before starting therapy. As always, consulting with a healthcare provider before starting tesamorelin therapy is essential, especially if you have a history of cancer, pituitary gland disorders, or chronic health conditions. Thanks for listening to The Peptide Podcast. If you found this episode helpful, be sure to subscribe and leave a review. And as always, have a happy, healthy week. If you're ready to dive deeper into the world of nutrition, don't miss my new ebook, Eat Smart: Powerful Tips for a Healthier You, now available on Amazon! It's packed with easy-to-understand, science-backed tips to help you optimize your diet, boost metabolism, and reduce inflammation. The best part? If you have Kindle Unlimited, it's always free! So grab your copy today and start your journey to a healthier, smarter way of eating!

Today, we're talking about sermorelin peptide therapy, an emerging peptide therapy option that's gaining attention for its potential benefits in anti-aging, muscle health, and overall vitality.  Whether you've heard about it before or are learning about it for the first time, this episode will break down exactly what sermorelin is, how it works, and why some people are turning to it for a boost in their health. Let's dive right in! What is Sermorelin? Sermorelin is a synthetic peptide that mimics the naturally occurring hormone growth hormone-releasing hormone (GHRH), which stimulates the pituitary gland to release growth hormone (GH). Growth hormone is important for various functions in the body, including growth during childhood, metabolism, muscle and bone health, and tissue repair. As we age, our natural production of growth hormone declines, which can contribute to symptoms like reduced muscle mass, increased body fat, lower energy levels, and other signs of aging. Sermorelin therapy is often used to boost the body's natural production of growth hormone, rather than injecting synthetic growth hormone directly. How Does Sermorelin Work? Unlike traditional growth hormone replacement therapies, where synthetic growth hormone is injected directly into the body, sermorelin therapy encourages your body to ramp up its own production of growth hormone. This is often seen as a more natural approach, with fewer potential risks associated with long-term synthetic growth hormone use. Typically, sermorelin is administered via subcutaneous injection (injected under the skin) given in the belly or upper thigh once a day or three to five times per week. The goal is to restore growth hormone levels to a more youthful range, improving overall health and well-being. Potential Benefits of Sermorelin Therapy So, what can sermorelin peptide therapy do for you? While results can vary, some of the potential benefits include: Improved Muscle Mass and Strength: Growth hormone plays a key role in muscle growth, and as sermorelin stimulates the pituitary to release more of it, many patients report an increase in muscle mass and strength over time. Fat Reduction: Sermorelin may help increase fat burning and promote lean muscle development, which can aid in weight loss and fat loss. Better Sleep Quality: Growth hormone is linked to deeper, more restful sleep. Many people undergoing sermorelin therapy notice an improvement in sleep patterns. Enhanced Energy Levels: With increased growth hormone production, some individuals experience a boost in energy, stamina, and overall vitality. Improved Skin Tone and Elasticity: Sermorelin may help stimulate the production of collagen, leading to firmer, more youthful-looking skin. Faster Recovery and Healing: Increased growth hormone levels can help with the repair of tissues and muscles, speeding up recovery from injuries or workouts. Better Mood and Mental Clarity: Some users report enhanced cognitive function, better mood, and a clearer mind, likely due to the overall improvement in physical health and hormone balance. Potential Side Effects and Risks As with any treatment, sermorelin peptide therapy comes with its own set of potential side effects and risks. Most people tolerate the therapy well, but some may experience mild side effects, such as: Injection site reactions: Redness, swelling, or irritation at the site of injection. Headaches: Some people report headaches, particularly when starting therapy. Flushing or dizziness: A warm, flushed feeling or dizziness may occur, though it's typically short-lived. Joint or muscle pain: Occasionally, users may experience discomfort in muscles or joints, especially in the early stages of therapy. Water retention: Some people might notice mild swelling or water retention. In rare cases, there can be more serious side effects, such as excessive growth hormone levels, which could lead to conditions like carpal tunnel syndrome, diabetes, and  joint enlargement. It's important to have regular check-ups with a healthcare provider to monitor any side effects and ensure the treatment is working as intended. Additionally, since sermorelin stimulates the body's natural production of growth hormone, it's important for individuals to be screened for underlying medical conditions such as pituitary gland issues or active cancer, as these could be aggravated by the therapy. If you're interested in exploring sermorelin therapy, talk to a healthcare professional who specializes in hormone replacement or peptide therapies to see if it's right for you. Thanks for listening to The Peptide Podcast. If you found this episode helpful, be sure to subscribe and leave a review. And as always, have a happy, healthy week. If you're ready to dive deeper into the world of nutrition, don't miss my new ebook, Eat Smart: Powerful Tips for a Healthier You, now available on Amazon! It's packed with easy-to-understand, science-backed tips to help you optimize your diet, boost metabolism, and reduce inflammation. The best part? If you have Kindle Unlimited, it's always free! So grab your copy today and start your journey to a healthier, smarter way of eating!

Fitness, Health, and Lifestyle Titan Medical CEO and Owner John Tsikouris talks about the benefits of GLP-1s! How it can affect lean muscle and weight loss. John answers questions from our live stream followers regarding hormones replacement therapy, muscle gains, blood work and gym advice!

Titan Medical Owner and CEO John Tsikouris goes live from our offices in Tampa, Florida! He Discusses the benefits of our new Titan Takeover bundle which is GLP-1 and Tesamorelin. Titan Medical can help you feel better and look better with these therapies. Have a question? Join us live!

In dieser 2. Episode zum Thema Schlaf dreht sich alles um körperliche Leistungsfähigkeit, Muskelaufbau und Fettreduktion. Denn was hat das alles mit Schlaf zu tun? Cortisol Supression Agent (CSA): https://www.big-zone.de/Big-Zone-C.S.A.-60-Kapseln/3372 -10% Rabatt mit dem Code "Larry10" Studienauszug: The somatropic axis and sleep, 2001. Ghrelin alone or co-administered with GHRH or CRH increases non-REM sleep and decreases REM sleep in young males, 2008

7/19: Titan Lifestyle! -Live Q&A with Titan Medical Athlete Big Dru Therapy of Week: Tesamorelin This FDA approved therapy is very similar to IGF-1 and MK 677. Tesamorelin is a synthetic form of GHRH. Titan Medical Center athlete and bodybuilder Big Dru, talks about Peptides, Titan Medical Center therapy Hercules Potion, Hormone Replacement Therapies, and much more! Have a question? Join us live every Friday at 2PM EST.

Fitness, Health, and Lifestyle Therapy of Week: Tesamorelin This FDA approved therapy is very similar to IGF-1 and MK 677. Tesamorelin is a synthetic form of GHRH. BENEFITS: * Weight-loss * Targets Belly Fat * Helps Increase Energy Levels * Increases IGF-1 Levels * Improves Lean Muscle * May Help Increase Strength * May Help Muscle Density * Helps Promote Anti- Aging Owner and CEO of Titan Medical Center, John Tsikouris gives an insight on targeting visceral belly fat with Tesamorelin. He also touches on the topics of today: Psychedelics could treat some of the worst chronic pain in the world and Blood proteins predict cancer risk seven years in advance. Have a question? Join us live!

Upon diagnosing acute myeloid leukemia (AML), the initial step involves assessing a patient's eligibility for intensive chemotherapy. The standard treatment protocol for newly diagnosed AML encompasses intensive chemotherapy to achieve complete remission, followed by post-remission therapy, which may include additional chemotherapy and/or stem cell transplantation. Complete response rates to this approach range from 60% to 85% in adults aged 60 or younger. While this approach has proven effective, the risk of relapse within three years of diagnosis remains a significant concern. Numerous factors contribute to the likelihood of relapse, including short duration of remission, genetic derangements, prior allogeneic transplantation, advanced age, and concomitant comorbidities. These negative prognostic factors underscore the need for continuous exploration of novel therapeutic agents, as relapse remains a formidable barrier to treatment success. In a new study, researchers Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally (awarded the Nobel Prize in Physiology or Medicine in 1977), and Joaquin J. Jimenez from the University of Miami, Florida Atlantic University and Veterans Affairs Medical Center, Miami, investigated newly emerging therapies targeting drug resistance in AML. On April 8, 2024, their new research paper was published in Oncotarget's Volume 15, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.” Full blog - https://www.oncotarget.org/2024/05/23/combating-doxorubicin-resistant-acute-myeloid-leukemia/ Paper DOI - https://doi.org/10.18632/oncotarget.28579 Correspondence to - Simonetta I. Gaumond - sxg1204@miami.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28579 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, leukemia, AML, resistance, growth hormone-releasing hormone, MIA-602 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

BUFFALO, NY- April 10, 2024 – A new #researchpaper was #published in Oncotarget's Volume 15 on April 8, 2024, entitled, “Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia.” Acute myeloid leukemia (AML) is characterized by the rapid proliferation of mutagenic hematopoietic progenitors in the bone marrow. Conventional therapies include chemotherapy and bone marrow stem cell transplantation; however, they are often associated with poor prognosis. Notably, growth hormone-releasing hormone (GHRH) receptor antagonist MIA-602 has been shown to impede the growth of various human cancer cell lines, including AML. In this new study, researchers Simonetta I. Gaumond, Rama Abdin, Joel Costoya, Andrew V. Schally, and Joaquin J. Jimenez from the University of Miami, Florida Atlantic University and Veterans Affairs Medical Center, Miami examined the impact of MIA-602 as monotherapy and in combination with Doxorubicin on three Doxorubicin-resistant AML cell lines, KG-1A, U-937, and K-562. “Given the role of GHRH in multiple cancer types, it is possible that GHRH antagonists may offer an alternative treatment approach for AML as well as drug-resistant AML, which may circumvent the side effects associated with standard chemotherapy.” The in vitro results revealed a significant reduction in cell viability for all treated wild-type cells. Doxorubicin-resistant clones were similarly susceptible to MIA-602 as the wild-type counterpart. Their in vivo experiment of xenografted nude mice with Doxorubicin-resistant K-562 revealed a reduction in tumor volume with MIA-602 treatment compared to control. “Our study demonstrates that these three AML cell lines, and their Doxorubicin-resistant clones, are susceptible to GHRH antagonist MIA-602.” DOI - https://doi.org/10.18632/oncotarget.28579 Correspondence to - Simonetta I. Gaumond - sxg1204@miami.edu Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, leukemia, AML, resistance, growth hormone-releasing hormone, MIA-602 About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Noradrenaline (norepinephrine) is a neurotransmitter and hormone that plays a role in the body's "fight or flight" response.  Acetylcholine is a neurotransmitter (“brain” +” across” + “to send”) that helps transmit signals in the brain and body. Its name comes from its chemical structure, an acetate group and a choline molecule.  Dopamine is a neurotransmitter that plays a role in motivation, reward, and movement. Its name comes from its chemical structure, a combination of two molecules called dihydroxyphenylalanine and dopamine. Adrenaline (epinephrine) is a hormone and neurotransmitter that helps the body respond to stress. Its name comes from its source, the adrenal glands.  Serotonin is a neurotransmitter that is involved in mood, appetite, and sleep. Its name comes from its chemical structure, a combination of sero- (meaning "serum") and -tonin (meaning "tonic" or "substance that modifies").  Corticotropin-releasing hormone (CRH) is a hormone that stimulates the release of cortisol, a stress hormone. The name comes from its function of stimulating the release of corticotropin, a hormone that stimulates the adrenal glands. Also, it gets its name from its role in stimulating the release of adrenocorticotropic hormone (ACTH) from the pituitary gland, which in turn stimulates the release of cortisol from the adrenal gland. Vasopressin is a hormone that regulates water balance in the body. Its name comes from its ability to constrict blood vessels (vasoconstriction) and increase blood pressure. Vasopressin, also known as antidiuretic hormone (ADH), is so named because it regulates water balance by causing the kidneys to reabsorb water. Thyrotropin-releasing hormone (TRH) is a hormone that stimulates the release of thyroid-stimulating hormone (TSH), which regulates the thyroid gland. Its name comes from its function of stimulating the release of thyrotropin.  Oxytocin is a hormone that is involved in social bonding, childbirth, and lactation. Its name comes from its ability to stimulate uterine contractions (oxytocic) and milk ejection (lactogenic).  Gonadotropin-releasing hormone (GnRH) is a hormone that stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which regulate the reproductive system. Its name comes from its function of stimulating the release of gonadotropins.  Growth hormone–releasing hormone (GHRH) is a hormone that stimulates the release of growth hormone (GH), which regulates growth and metabolism. Its name comes from its function of stimulating the release of growth hormone.  Catecholamines are a group of hormones and neurotransmitters that includes adrenaline, noradrenaline, and dopamine. Their name comes from their chemical structure, which includes a catechol group and an amine group.  Histamine is a neurotransmitter and hormone that is involved in inflammation, allergies, and gastric acid secretion. ACTH (adrenocorticotropic hormone) is a hormone that stimulates the release of cortisol from the adrenal glands.  Orexin (hypocretin) is a neurotransmitter that is involved in wakefulness and appetite. Its name comes from its discovery in the hypothalamus and its ability to stimulate food intake (orexigenic).  Glutamic acid (glutamate) is a neurotransmitter that is involved in learning, memory, and neural plasticity. Its name comes from its chemical structure, a combination of glutamine and an acid group.  Galanin is a neuropeptide that is involved in pain perception, mood, and appetite. Its name comes from its discovery in the galanin-containing neurons of the hypothalamus.  Neurotensin comes from the words "neuro," meaning related to nerves, and "tensin," which refers to its ability to cause contraction in smooth muscle. Neurotensin is a neuropeptide that is found in the central nervous system and gastrointestinal tract. --- Support this podcast: https://podcasters.spotify.com/pod/show/liam-connerly/support

Heart failure with preserved ejection fraction (HFpEF) is, in many ways, a fascinating tale of modern cardiovascular medicine that, according to lead author Dr. Joshua Hare (University of Miami Miller School of Medicine), has taught cardiovascular researchers and clinicians a lot of humility. Understanding HFpEF in a variety of animal models has led to a paradigm shift away from heart failure linked to low ejection fraction. In this episode Associate Editor Dr. Jonathan Kirk (Loyola University Chicago Stritch School of Medicine) interviews Dr. Hare along with expert Dr. Julie McMullen (Baker Heart and Diabetes Institute, Melbourne, Australia) about the latest study by Kanashiro-Takeuchi et al. The Hare Lab was originally attracted to a cardiometabolic model of HFpEF pioneered by Dr. Joseph Hill, because in a large proportion of human patients, HFpEF is due to metabolic syndrome, which is a combination of obesity, diabetes, and hypertension. Armed with the ability to create this cardiometabolic HFpEF model, Hare and co-authors decided to test growth hormone-releasing hormone-agonist using a powerhouse of methods to determine if exercise intolerance could be improved. Kanashiro-Takeuchi et al. found that diastolic function and exercise performance improved, and myocyte hypertrophy and fibrosis were restored. Essentially all of the features of cardiometabolic HFpEF responded to treatment with GHRH-agonist. The authors did not see a reduction in blood pressure or weight, indicating a direct myocardial effect. In a wide-ranging discussion that touches on skeletal muscle, aging, sarcomeric proteins, and the technical complexities of running titin gels and PV loops, our experts explain why HFpEF is such a challenging syndrome to treat and why this translational research is so important. Listen now.   Rosemeire M. Kanashiro-Takeuchi, Lauro M. Takeuchi, Raul A. Dulce, Katarzyna Kazmierczak, Wayne Balkan, Renzhi Cai, Wei Sha, Andrew V. Schally, Joshua M. Hare Efficacy of a Growth Hormone-Releasing Hormone Agonist in a Murine Model of Cardiometabolic Heart Failure with Preserved Ejection Fraction Am J Physiol Heart Circ Physiol, published April 25, 2023. DOI: 10.1152/ajpheart.00601.2022.

Your hosts Stevesmi and Da Mobster discuss Peptides for iTunes with this one being Sermorelin (GRF 1-29) doses, cycles, benefits and its side effects • Just what is Sermorelin and why would you pick this over another peptide • Why you need a GHRP with a GHRH like Sermorelin to get the best from it. • Its crazy short half life of just 10 minutes • We debate both benefits and side effects • How to optimize the timing of an injection around the gym and sleep • How you have the best access to information in history right now • Why an anti-ageing peptide is useful • Suggested dosing • As always we talk about how to prepare and store it as well as where best to inject it. Link to article: https://www.evolutionary.org/sermorelin-GRF-1-29-peptide Links to Evo threads: 1. https://www.evolutionary.org/forums/anabolic-steroids-peds/got-simple-sermorelin-question-46980.html 2. https://www.evolutionary.org/forums/anabolic-steroids-peds/sermorelin-bodybuilding-48495.html 3. https://www.evolutionary.org/forums/anabolic-steroids-peds/best-cardarine-sermorelin-get-where-get-them-65874.html 4. https://www.evolutionary.org/forums/anabolic-steroids-peds/ghrp-2-a-5671.html 5. https://www.evolutionary.org/forums/anabolic-steroids-peds/expired-hgh-11898-2.html For 1-on-1 coaching/consultation/source help requests hit up Stevesmi https://www.elitefitness.com/forum/members/stevesmi.html https://www.evolutionary.org/forums/members/stevesmi.html Where to get blood tests: https://www.evolutionary.org/forums/source-talk/bloodwork-private-md-5695.html Please note we're not doctors and the opinions are ours. It's our view and is based on our experience and views on the topic. Our Podcasts are for informational purposes and entertainment only. The Freedom of speech and 1st amendment applies.

Today we are talking about CJC 1295 and its potential benefits. All this and more in less than 2 minutes.  An excellent example of the ability peptides have to work together with our own bodies comes from a few of the most commonly used peptides available for anti-aging: growth hormone-releasing hormones (or GHRHs) and growth hormone-releasing peptides (GHRPs).  As you know, aging is essentially our bodies breaking down at the cellular level. As we age, we deal with things like decreased muscle mass, decreased immune function, a decreased sex drive, increased skin issues, change in mood, the list goes on and on.  All of this along with depression, and many more unwanted effects seem to inevitably come as part of the aging process. Some of this dysfunction can be treated with GHRH peptides like CJC-1295 or GHRP peptides like Ipamorelin or a combination of BOTH! Today we are going to focus on CJC 1295. What is CJC 1295? CJC 1295 is a lab-made peptide hormone, primarily functioning as a GHRH or amplifier. In simple terms, the peptide increases protein synthesis, human growth hormone (aka HGH) secretion, and insulin-like growth factor (or IGF-1).  IGF-1 is a hormone that's similar in molecular structure to insulin and plays an important role in childhood growth and has anabolic effects (or muscle-building effects) in adults.  What are the BENEFITS?  CJC 1295 is useful to those looking to increase lean muscle mass and strength by stimulating the release of growth hormone. It also promotes muscle recovery as it boosts protein synthesis levels and helps the growth of muscle tissues resulting in quicker recovery times for athletes and those with injuries. And because it stimulates the production of IGF-1, it can help decrease body fat and increase natural strength. Compared to other peptide therapies, CJC 1295 has a longer half-life of 30 minutes which requires fewer peptide injections and results in the continual release of growth hormone.  It also has minimal effect on cortisol levels. Cortisol is a hormone that's released into your bloodstream when your body undergoes stress. This hormone causes an increase in your heart rate and blood pressure. It's your natural “fight or flight” response. However, over time, if your body experiences repeated stress, you may begin to feel tired, irritable, depressed, and even experience weight gain.   BUT DOES IT WORK? Peptide therapies are not miracles in a bottle. They don't guarantee desired results. Like anything in life, you must also make lifestyle changes when it comes to certain desired outcomes. For example, a poor diet and lack of exercise can have a negative impact on your health and cause weight gain, joint pain, and can even lead to type 2 diabetes. Peptide therapy in addition to healthy lifestyle choices can help you achieve your health goals! Possible side effects include redness or itching at the injection site. You should tell your healthcare provider about any side effects you think you may be experiencing.  You can find more information at pepties.com.  That's peptides without the D. Where we are tying all the peptide information together in one easy place. Thanks again for listening to The Peptide Podcast, we love having you as part of our community. If you love this podcast please share it with your friends and family on social media. And subscribe to our podcast. Have a happy, healthy week!

Welcome to CHS(Clinical Hormone Studies) Episode 3, where we attempt to break down some of the world's most bizarre cases of hormones gone absolutely wrong. I'm your host, Suraj Oruganti, and today we will be talking about GHRH, a hormone that is in charge of releasing the growth hormone. We will be going over how GHRH works in the body when functioning properly, what happens when GHRH starts to go awry, and some case studies of how these problems were fixed.

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2020.08.17.254862v1?rss=1 Authors: Lima, J., Debarba, L. K., Khan, M., Ubah, C., didyuk, o., Ayyar, I., Koch, M., Sadagurski, M. Abstract: Growth hormone (GH) receptor (GHR), expressed in different brain regions, is known to participate in the regulation of whole-body energy homeostasis and glucose metabolism. However, GH activation of these GHR-expressing neurons is less studied. We have generated a novel GHR-driven Cre recombinase transgenic mouse line (GHR cre) in combination with the floxed tdTomato reporter mouse line we tracked and activated GHR-expressing neurons in different regions of the brain. We focused on neurons of the hypothalamic arcuate nucleus (ARC) where GHR was shown to elicit a negative feedback loop that regulates GH production. We found that ARC GHR+ neurons are co-localized with AgRP, GHRH, and somatostatin neurons, which were activated by GH stimulation. Using designer receptors exclusively activated by designer drugs (DREADDs) to control GHR-ARC neuronal activity, we revealed that activation of GHR-ARC neurons was sufficient in regulating distinct aspects of energy balance and glucose metabolism. Overall, our study provides a novel mouse model to study in vivo regulation and physiological function of GHR-expressing neurons in various brain regions. Furthermore, we identified for the first time specific neuronal population that responds to GH and directly linked it to metabolic responses in vivo. Copy rights belong to original authors. Visit the link for more info

bengreenfieldfitness.com/416     News Flashes –  for more…5:00           [5:40] Those who want to lose weight but don’t want to give up their beer will find this study quite compelling: alcohol (especially beer) seems to be OK if you’re doing HIIT training:          [9:05] Alcohol consumption following a workout doesn’t seem to affect the majority of the biological and physical benefits, but cortisol increased, and testosterone and muscle protein synthesis decreased, so long term muscular adaptations could be impaired if alcohol consumption during recovery is consistent: (Alcohol is a well known HGH acting at the GHRH level inhibitor/supressor and it also leads to IGF-1 decrease. Surprising it's not mentioned in the study.)              [13:00] Chalk another one up to the life-extending benefits of low-to-moderate alcohol consumption, at least in         [20:45] Israeli firm says  (500mcg!) with no high           [23:45] An interesting idea: Use your old coffee grounds by drying them, mixing into foods, and then burn more fat by changing your gut biome?         Listener Q&A:     How To Reverse Gray Hair...36:34       The Adrenal Fatigue Myth...55:30       How To Recover From COVID-19...1:07:35     Episode sponsors: Kion Coffee, Organifi, Seed Daily Synbiotic, Paleo Valley   bengreenfieldfitness.com/416

In an attempt to recover from the last episode’s derailment by boy bands, Ruka speeds through an overview of the hypothalamus and the anterior pituitary. In the process, she discovers Libby’s deep past with the movie Cool Runnings. Key Words - New record: 46! adrenal cortex, adrenaline, adrenocorticotropic hormone (ACTH), anterior pituitary, biogenic amine, catecholamine, corticotropin, corticotropin-releasing hormone (CRH), dopamine, endocrine feedback loop, epinephrine, estradiol, follicle-stimulating hormone (FSH), germ cell, gonadotropin-releasing hormone (GnRH), gonadotropins, gonads, growth hormone (GH), growth hormone release inhibiting hormone (GHRIH), growth hormone-releasing hormone (GHRH), homeostasis, hypothalamo-pituitary-adrenal (HPA) axis, hypothalamo-pituitary-gonadal (HPG) axis, infundibulum, insulin-like growth factor 1 (IGF-1), luteinizing hormone (LH), median eminence, melanocyte, melanocyte-stimulating hormone (MSH), melanocyte-stimulating hormone release-inhibiting factor (MIF), melanocyte-stimulating hormone-releasing factor (MRF), ovaries, ovum, parvocellular neurons, peptide hormone, portal vasculature, progesterone, prolactin, somatostatin, sperm, testes, testosterone, thyroid-stimulating hormone (TSH), thyrotropin-releasing hormone (TRH), thyroxine, triiodothyronine Old West Word of the Day (Gap Junction Almanac) Oof Related Episode Episode 14: Turkey Saddle [Hypothalamus and Posterior Pituitary] References and Resources Textbooks Vander’s Human Physiology, 13th Edition Principles of Neural Science, Kandel, Schwartz, and Jessell, 4th Edition Fundamental Neuroscience for Basic and Clinical Applications, Haines, 3rd Edition   Connect with us! FB @HeadshakeShow T @HeadshakeShow ‘Sta @HeadshakeNinja Site headshake.show OR headshake.ninja   Music Bushwick Tarantella by Kevin MacLeod is licensed under a Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) Source: http://incompetech.com/music/royalty-free/index.html?isrc=USUAN1300002 Artist: http://incompetech.com/ Modified from original with volume fading and cuts   Disclaimer This podcast is for entertainment and education only. Neither of the hosts is a medical doctor, and nothing they say is medical advice. Please consult with your physician before making decisions about your health.

Dr. Michael Moeller, NMD is a gentleman, a doctor, and a scholar of optimizing men's health. He is a naturopathic physician who is the founder of Infinity Medicine and Wellness in Laguna Hills, California. He specializes in peripheral neuropathy regeneration, men's hormones, and men's health.  Today on the podcast we talk about growth hormone releasing peptides, growth hormone releasing hormones, and immunity. These peptides govern optimizing lean mass and muscle gains, sleep, immune health, and stimulate your body's recovery.  Here are a few of the peptides we speak about: Growth hormone releasing peptides Ipamorelin MK677  Ibutamoren GHRH - Growth Hormone Releasing Hormone Sermorelin Tesamorelin CJC 1295 Body Protecting Compound  BPC 157 Immune peptides Thymosin Beta 4 (TB-500) Thymosin Alpha 1 (TA-1) Sexual enhancement Bremelanotide - PT 141  I hope you guys enjoy today's episode! Jump on Youtube and check out more video with Dr. Michael Moeller (Dr. Moe) today.  Links:  Dr. Moeller's website  I   https://www.drmichaelmoeller.com/ Four peptides for immune function I Dr. Michael Moeller NMD Dr. Moeller's prolific YouTube channel Dr. Raisanen's healing with peptides - blog post  Dr. Raisanen's TRT article

See all the Healthcast at https://www.biobalancehealth.com/healthcast-blog/ The brain is complex and is not a static organ. It is always growing new cells and breaking down the old cells. Like the rest of the body the brain is in a state of flux all the time. As we age without our sex hormones and growth hormones, breaking down occurs more rapidly than regrowth and our brain literally shrinks Another quite rapid symptom is the loss of short -term memory at the time before menopause when testosterone and GH decrease to a critical level. These hormone losses trigger the diverting of the brain blood flow from the area of the brain that holds recent memories. This causes immediate loss of words you are looking for when trying to describe something or someone. Most people forget names of people and places. There is loss of special ability like the function you need to discern the length or size of something or interpret architectural plans. This immediate memory loss reverses in the first 6 months of testosterone replacement, if it is within the first 10 years after testosterone levels drop. “An Italian study in 2000 demonstrated that there is a cognitive impairment without dementia which increases with age and is more prevalent in women than men” “In the same year, Dr. Capurso and researchers at the university of Bari found an age -related decline in cognitive function that causes a mild deterioration in memory performance, executive functioning and speed of cognitive processing” “The study concludes that the aging associated cognitive decline may be preventable and suggest the following: Avoidance of cardiovascular and other chronic diseases Attaining a high -level education Maintenance of vision and hearing capacities. Dr. Maupin believes that brain function can be protected from decline by taking testosterone, estradiol (for women), keeping thyroid function and growth hormones optimal. Several studies reveal the truth that replacement of testosterone in the first 10 years after its decline, can delay the onset of Alzheimer's disease and dementia for 10 years after it would normally occur. Other studies on women showed that replacement of estradiol in any form delayed the onset of these diseases of aging brain by 10 more years if it is taken in the window of 10 years after menopause. This reveals how important the sex hormones are to our brains. We also want to talk about muscle mass, strength, and stamina and aging. The amount of muscle mass you maintain depends on how much testosterone and growth hormone you produce or replace, the amount and kind of exercise you do, the genetic composition of your muscle such as do you have 100% slow twitch muscle which gives you the ability for long distance and long lasting strenuous exercise, or 100% fast twitch muscle which makes you good at short spurts of muscle work, lifting weights, and short but powerful muscle work of any kind or were you born with a combo? Diet/Nutrition is also important because you can -not build muscle without the building blocks from animal protein. When you are given replacement hormone of testosterone, it stimulates your production of growth hormone which you make naturally. This is important because age related reduction in growth hormone is one of the most robust endocrine markers of biological aging. The reduction of GH and IGF-1 impairs reference memory and seems to be reversable with the administration of GHRH. (growth hormone releasing hormones). “muscle strength is a critical component of the ability to walk and to avoid falls and fractures. Reduced muscle strength as we age is a major cause for an increased prevalence of disability. If we can prevent the loss of muscle as we age, we will age more slowly and remain independent as we grow older. Advancing adult age is associated with profound changes in body composition, the principal component of which is a decrease in skeletal muscle This age-related loss of skeletal muscle is referred to as sarcopenia.” “Studies indicate that age related decline in skeletal muscle may contribute to such age associated changes as reduction in bone density, insulin sensitivity, and aerobic capacity.” The final component of this week's conversation references the sensory system. The principal conclusion of the discussion regarding the loss of sense of taste and smell, hearing and sight, suggests that attending to: Nutrition Hormones Lifestyle May expand your lifespan, while, at the same time, enhance the quality of that human life.

12/3/19: On today’s Titan Talk (broadcast live at 6pm on Facebook, Instagram & Youtube!) Titan Medical Center CEO John Tsikouris goes over: Therapy of the week: CJC 1295 with Ipamorelin -GHRH: growth hormone releasing hormone -GHRP: growth hormone releasing peptide What are the benefits of these things? What do they do? Any negative side effects? -EDC endocrine disrupting chemicals (plastic) BPA -Micro plastics -Upcoming events: Kenzilla’s Lift for Gifts! BIG TITAN NEWS: -The Titan Program App -New location is almost done then it’s Grand Opening date/time! -Our new show on ABC in Florida from Sarasota to Crystal River. Tune in Sunday’s 11 AM soon! -Titan gear giveaway #titangear -Titan Weekly Newsletter Code Word Giveaway! Go to our 12/2/19 TITAN Weekly Newsletter: CJC 1295 with Ipamorelin! Events & Updates! (DIRECT Email Link https://conta.cc/2qWJaK8) & pick the code word John gives during this live to win FREE Titan Clothing gear! Choices are: Mandalorian, Injectables & Winter. Follow us on our social media, YouTube, & listen to us on our Titan Medical podcast! Don’t forget to join us on Friday when we go live with Titan Athlete Big Dru at 2pm! titanmedical #medicalscience #health #advice #tampa #therapy #medicalclinic #johntsikouris #medicalproviders #medicaladvice #ipamorelin #cjc1295 Titan Medical Center CEO John Tsikouris goes live on his Instagram and Facebook video feeds every Tuesday at 6pm (Titan Talk Tuesdays) and talks to his viewers and answers questions about health, fitness and medical science. We air the episodes here as soon as they're finished for your listening convenience.

Ghrelin ist der natürliche Ligand des wachstumshormon-sekretagogen (GHS)-Rezeptors (Kojima, 1999). Es stimuliert die Wachstumshormon (GH)-Ausschüttung an der Hypophyse und wirkt appetitsteigernd. Bisherige schlafendokrinologische Untersuchungen zeigen, dass die Hormone wachstumshormon-freisetzendes-Hormon (GHRH), Somatostatin, corticotropin-freisetzendes Hormon (CRH) und Cortisol in die Schlafregulation involviert sind. Auch synthetische Wachstumshormon-Sekretagoge (GHS) modulieren beim Menschen den Schlaf und beeinflussen die nächtliche hormonellen Sekretion. Ziel dieser Arbeit war es, die Effekte von Ghrelin auf das Schlaf-EEG und die nächtliche Hormonsekretion von GH, ACTH, Cortisol, Prolaktin und Leptin bei jungen gesunden Männern zu untersuchen. Nach Gabe von 4 x 50 µg Ghrelin iv. zu Beginn der Nacht fand sich ein signifikanter Anstieg des Tiefschlafs im Schlaf-EEG und der assoziierten nächtlichen GH-, Cortisol- und Prolaktin-Sekretion. Die Leptinspiegel waren nicht signifikant verändert. Diese Arbeit konnte zeigen, dass exogen appliziertes Ghrelin signifikante Wirkungen auf den humanen Schlaf und die schlafassoziierte Hormonsekretion ausübt. Anhand der Ergebnisse ist davon auszugehen, dass Ghrelin nicht nur auf die GH-Sekretion, das Appetitverhalten oder das Gewicht Einfluss nehmen kann, sondern eigene endogen-schlafmodulierende Effekte ausübt und bei jungen gesunden Männern als tiefschlaffördernder Faktor angesehen werden kann. Weiterhin bewirkt Ghrelin einen deutlichen Effekt auf die somatotrophe und corticotrophe Hormonsekretion, indem es die physiologischen Sekretionsmuster von GH und Cortisol stimuliert und intensiviert. Bei Betrachtung der gegensätzlichen Wirkungen der einzelnen Hormone GHRH und CRH auf den Schlaf ist dabei bemerkenswert, dass Ghrelin die GH-sekretagogen und tiefschlaffördernden Effekte von GHRH und die Cortisol-sekretagogen Effekte von CRH vereint. Man kann postulieren, dass Ghrelin eine mögliche Schnittstelle des somatotrophen und des corticotrophen Systems darstellt.

Repeated injection of GHRH leads to a decrease in the GH response in normal subjects. Arginine (Arg) stimulates GH secretion by suppression of hypothalamic somatostatin. To confirm these findings, eight normal men were examined in a series of five settings: test 1 (GHRH/GHRH-TRH), 100 micrograms GHRH injected iv, followed by 100 micrograms GHRH, iv, after 120 min and 200 micrograms TRH, iv, after 150 min; test 2 (GHRH/Arg-TRH), like test 1, but instead of the second GHRH injection, a 30 g Arg infusion over 30 min; test 3 (GHRH/GHRH-Arg-TRH), like test 1, but additionally a 30 g Arg infusion after 120 min; test 4 (GHRH-Arg-TRH), iv GHRH and Arg infusion initially, followed by iv TRH after 30 min; and test 5 (TRH), 200 micrograms TRH, iv, at 0 min. For statistical evaluation, the area under the GH curve (AUC) from 0-120 min was compared with the AUC from 120-240 min. The GH response to the second administration of GHRH was significantly lower (P < 0.02) than the first increase [AUC, 0.5 +/- 0.01 min.mg/L (mean +/- SE) vs. 1.2 +/- 0.3]. No significant differences were found between the GH responses to either GHRH or Arg alone (AUC, 0.9 +/- 0.2 min.mg/L vs. 0.9 +/- 0.2). A larger GH increase (P < 0.02) was seen after GHRH-Arg compared to GHRH alone (AUC, 1.9 +/- 0.4 min.mg/L vs. 1.2 +/- 0.3). The GH response (P < 0.02) to GHRH-Arg stimulation was lower after previous GHRH injection than after GHRH-Arg stimulation alone (AUC, 1.9 +/- 0.4 min.mg/L vs. 3.5 +/- 0.9). There was a statistically significant difference between the TRH-stimulated TSH response in test 4 compared to that in test 5. We could show that decreasing GH responses to repeated GHRH can be avoided by a combined stimulation with GHRH/Arg. These findings suggest that the decreased GH response to a second GHRH bolus may be partly due to an elevated hypothalamic somatostatin secretion, which can be suppressed by Arg. The lower GH response to GHRH-Arg stimulation after a previous GHRH bolus suggests, furthermore, that the readily available GH pool in the human pituitary may be limited.

The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism. To determine the effect of GHRP on human somatotroph cells in vitro, we stimulated cell cultures derived from 12 different human somatotroph adenomas with GHRP alone and in combination with GH-releasing hormone (GHRH), TRH, and the somatostatin analog octreotide. GH secretion of all 12 adenoma cultures could be stimulated with GHRP, whereas GHRH was active only in 6 adenoma cultures. In GHRH-responsive cell cultures, simultaneous application of GHRH and GHRP had an additive effect on GH secretion. TRH stimulated GH release in 4 of 7 adenoma cultures; in TRH-responsive cell cultures there was also an additive effect of GHRP and TRH on GH secretion. In 5 of 9 adenoma cultures investigated, octreotide inhibited basal GH secretion. In these cell cultures, GHRP-induced GH release was suppressed by octreotide. In 5 of 5 cases, the protein kinase-C inhibitor phloretin partly inhibited GHRP-stimulated GH release, but not basal GH secretion. In summary, GH secretion was stimulated by GHRP in all somatotroph adenomas investigated, indicating that its unknown receptor and signaling pathway are expressed more consistently in somatotroph adenoma cells than those for GHRH, TRH, and somatostatin. Our data give further evidence that GHRP-stimulated GH secretion is mediated by a receptor different from that for GHRH or TRH, respectively, and that protein kinase-C is involved in the signal transduction pathway. Because human somatotroph adenoma cell cultures respond differently to various neuropeptides (GHRH, TRH, somatostatin, and others), they provide a model for further investigation of the mechanism of action of GHRP-induced GH secretion.